Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988827 | 1.00 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL16419134 | 1.00 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL30988794 | 1.00 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL22785842 | 1.00 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6490320 | 0.86 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL801059 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3920742 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7784227 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7102577 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL1445942 | 0.84 | AOC3 (0.69) | AOC3L3MBTL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | disclosed |
| EP-2822928-B1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr Reddys Laboratories Ltd (IN) | 2018-11-14 | — | — | EP | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | disclosed |
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | AOC3 1464/4885L3MBTL1 1342/4885CHRM2 3723/4885 |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | AOC3 1068/4885L3MBTL1 2398/4885CHRM2 123/4885 |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | AOC3 1069/4885L3MBTL1 2424/4885CHRM2 120/4885 |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | OPRK1, OPRL1, OPRD1 | AOC3 1069/4885L3MBTL1 2424/4885CHRM2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.